Veradigm Ambient Scribe

Two independent reasons converge on C. First the platform not algorithm precedent applied across this category to ModMed, Elation Health, Oracle Health and NextGen: the module sits inside the Veradigm EHR and nobody selects Veradigm because of it. Second, and more decisive, the model is not Veradigm's. The product is expressly powered by AvodahMed, which places Veradigm in the position this index graded HeartSciences on, distributing a third party algorithm rather than owning one.

Credit where due: Veradigm names its OEM in its own launch materials rather than presenting the intelligence as its own, which is more candour than most white label arrangements offer. The grade describes the mechanism, not the quality of the output.

Sits on the conservative side of the split now running through this category. Diagnosis codes are presented as ICD-10 SUGGESTIONS for provider review rather than pre filled, and no evidence was found of ambient order or prescription drafting of the kind Oracle Health and Sunoh.ai ship.

One capability to watch: real time clinical insight prompts tuned to practice protocols surface care considerations during the encounter, which edges from documentation into decision support and carries a different risk profile from note generation. Held at B because no confidence threshold, acceptance rate or edit burden figure is published.

The pipeline is described at a high level, speech to text producing a transcript which machine learning and natural language processing convert into a note, which is more mechanical detail than several competitors give. Beyond that there is no accuracy figure, no evaluation methodology, no model card and no named models.

The OEM structure adds a second layer of opacity a buyer should account for: the party accountable for model behaviour is AvodahMed, whose own disclosures are separate from Veradigm's, so diligence questions asked of Veradigm may not be answerable by Veradigm.

This record introduces a form of the axis that will recur across the index and it is one of the more consequential ones: the relabelled engine. The ambient capability is delivered through an original equipment manufacturer arrangement, and the party accountable for model behaviour is AvodahMed rather than Veradigm.

Naming the company that actually builds the model is precisely what this axis asks for, and it is a better disclosure than most direct vendors in this lane manage, because a buyer can go and read the supplier's own material rather than being told the technology is proprietary. Hence the grade. What holds it below the top is that the disclosure stops at the first link.

Nothing below AvodahMed is named, so no foundation model provider, model class or version is established, no hosting arrangement is published for the combined product, and no sub processor list was located for either party. The two companies publish separately and their disclosures do not join up, which means a chain exists on paper without a single document that describes it end to end.

The practical consequence belongs in diligence and it is unusual enough to state plainly: the counterparty a buyer contracts with is not the party that can answer questions about the model, so security and model questionnaires sent to Veradigm may need to be answered by a company the buyer has no agreement with. Ask for the supplier's disclosures directly and ask which entity carries the representations.

Named physician testimonials only, including a medical director quoted at launch and a family medicine physician reporting improved documentation quality after six months of use. No study, no controlled comparison, no accuracy benchmark and no third party performance rating located. Graded C on the standing precedent that satisfaction anecdotes do not substitute for evidence of benefit.

Contains the single most interesting privacy claim located in this category, and is held at B only because it needs confirming.

Veradigm describes the capture path as using speech to text to create real time encounter transcripts without generating audio recordings. If that holds contractually it is engineered privacy rather than promised privacy, in the same class as Inspiren's camera free sensor design, because an audio artifact that never exists cannot be retained, breached, subpoenaed or used for training.

The claim appears in a Veradigm explainer article rather than a product security page or trust centre, and no retention schedule or training use statement was located, so this is the first thing to get in writing. Confirmed, it would be an A.

No product specific business associate agreement posture, template or scope statement was located.

The earlier assessment flagged the OEM structure as worth pressing. The second pass confirms it and shows why this is the sharpest version of that problem in the category rather than an ordinary partner arrangement.

The product carries the record system vendor's own name. It is sold to that vendor's customers, launched under that vendor's brand, and announced by that vendor's chief executive. It is also, by the vendor's own attribution, powered by a separate company, and the two organisations describe having worked together specifically so the scribe runs inside the record system without the clinician leaving it.

That combination is precisely the arrangement in which a buyer assumes their existing agreement covers everything. A practice already contracted with its record system supplier, buying an additional module from that same supplier under that supplier's brand, has every reason to believe the protected health information stays inside a relationship it has already papered. The processing is performed by a different legal entity.

So the questions are specific rather than general. Establish whether the partner is named as a subcontractor in the agreement chain, on what terms, whether the buyer has visibility of those terms or only of the prime relationship, what happens to the data the partner holds if the partnership ends, and who is accountable to the buyer in a breach originating with the partner.

One further layer is worth asking about. The partner's parent operates a language translation division alongside its digital health division, and the scribe has since added multilingual support. Establish whether that capability is delivered by the same entity or introduces another.

No named or dated attestation for this module, and no trust centre, was located in a second pass.

Two routes that sometimes yield on this axis both fail here, and saying why is more useful than repeating the absence.

The filing route does not apply. This vendor is quoted on the over the counter market rather than a national exchange, and an over the counter quotation carries no annual cybersecurity governance disclosure obligation, so there is no equivalent of the processes description this index has used to reach a grade for listed vendors elsewhere.

The marketplace route does not substitute for one either, and this is the point a buyer is most likely to get wrong. The product appears in the record system vendor's own application marketplace, which reads as endorsement. That marketplace's own notice states that listed applications have either self reported that their solution is production ready for its customers, or, where indicated, have been tested through a certification process available to participants. Self reported readiness and tested certification are two different things sitting in the same catalogue, and the notice says so plainly. Presence in an established vendor's marketplace is therefore not evidence that anything was examined.

The OEM structure compounds it. Any attestation that mattered would need to cover the partner actually processing the encounters, not only the brand on the product, and no attestation for either was located in relation to this module.

The grade reflects what a counterparty can verify before contracting rather than a judgement that controls are absent. Ask which entity holds a report, of which type and period, and whether its scope covers the ambient module specifically rather than the record system estate around it.

No clearance claimed and none required for ambient documentation. No United States device pathway attaches to a note the clinician reviews and signs.

The scope has moved since the earlier assessment and the vendor's own release language is the evidence. The product now includes structured diagnosis code recommendations, automatically identifying and recommending ICD-10 codes, alongside what the vendor calls clinical decision insights support tools, plus multilingual support. It also writes discrete structured data such as vital signs into the record rather than narrative alone.

Two boundaries follow from that. Diagnosis code recommendation is the reimbursement boundary, since the codes proposed shape what is billed. Decision support is named by the vendor in the feature itself, which is a more explicit acknowledgement than most in this category offer and is worth crediting as candour even as it identifies the boundary being crossed. The question to put is the standard one: what the insights are grounded in and what the clinician is shown to support them, since the reasoning that keeps clinical decision support outside device regulation depends on a professional being able to review the basis rather than rely on the conclusion.

One structural point is specific to this record. The product is branded by the record system vendor and built by a partner. No device pathway attaches today, so the question is currently academic, but it is worth noticing that if any component of this suite were ever to cross into regulated territory, the manufacturer of record would need establishing between the brand owner and the builder. Buyers of white labelled clinical AI should ask that question early rather than at the point it matters.

Markets appear to be United States only, and availability is limited to the record system vendor's own customer base.

One honest scope statement, no governance disclosure. The honest part: Veradigm states that multilingual capture produces ENGLISH documentation output, which tells a buyer plainly that the note will not be in the language the visit was conducted in. Most vendors marketing multilingual capability blur exactly that distinction.

What is absent is everything else: no fairness statement, no subgroup analysis, no accent or dialect performance disclosure, and no acknowledgement that a transcript produced from a non English conversation and rendered into English involves a translation step whose errors are invisible to a reviewer reading only the output.

Two passes located no accuracy or error figure, no published limitations, no warranty or indemnity language and no remediation commitment for this product. The structural point is what makes the absence worth more than a shrug. The ambient capability is supplied through an original equipment manufacturer arrangement, so the model is built by one company and sold under another's name, and the buyer's contract runs to the reseller. That splits the two things this axis measures.

The party with a commercial relationship to the customer is not the party that controls model behaviour, and the party that controls model behaviour has no relationship with the customer at all. A health system asking what happens when the note is wrong is therefore asking a question its own counterparty may not be able to answer, and cannot unilaterally fix. One published claim is worth confirming precisely because it would change the picture if it holds.

The capture path is described as producing real time transcripts without generating audio recordings at all, which would be a privacy property built into the architecture rather than promised in a policy. It appears in an explainer article rather than in security documentation, so it is not relied on here. Ask which entity carries the performance representations, whether the reseller passes through any supplier warranty, and get the no audio design confirmed in the contract if it is real.

Deep inside Veradigm and unavailable outside it, the same shape as the other EHR native scribes here. Notes land directly in the Veradigm EHR, capture runs through a dedicated mobile application, and enhancements reach customers through phased rollout without system upgrades or lengthy implementation cycles, which is a genuine advantage of native delivery. Worth noting that Veradigm also runs an app marketplace listing competing scribes, so native does not mean exclusive even inside its own base.

No hosting region, residency option or subprocessor list was located, and this is the record in the lane where that last gap matters most, because the subprocessor is not hypothetical. It is named on the product.

The scribe is branded by the record system vendor and powered by a separate company, with the two describing deep integration so the encounter starts without the clinician leaving the record system. That means encounter audio and transcript are processed by an organisation other than the one the buyer contracts with, as the ordinary operating design rather than as an edge case. Everywhere else in this lane the question this axis asks first, whether a third party processes the encounter, is unanswered. Here it is answered affirmatively on the box, and everything after it is unanswered: where that partner processes, what it retains, for how long, and under what terms with the brand owner.

The integration depth cuts both ways and a buyer should see both. Running inside the record system is a genuine usability gain and the vendor is explicit that this was the point of choosing this partner over a lightly integrated alternative. Deeper integration also means the partner's software is reaching further into the record, and the product now writes discrete structured data such as vital signs into the chart rather than only narrative text.

A further layer is worth establishing. The partner's parent operates a language translation division alongside its digital health division, and multilingual support has since been added to the scribe. Whether that capability is delivered by the same entity, a sibling, or a further third party changes the subprocessor map again.

Ask for the subprocessor list, the hosting region for each party in the chain, and what the partner retains after a note is delivered.

No published rate card and no standalone price. Sold within the Veradigm EHR relationship. One procurement fact belongs in the commercial assessment rather than buried: Veradigm's own investor releases carry the ticker OTCMKTS MDRX, meaning the parent trades over the counter rather than on a national exchange. That is a supplier continuity question of the kind this index has flagged before, and it applies to the party carrying the contract rather than to the quality of the product.

Ambulatory, bounded by the Veradigm installed base, and thinly documented. Note types named are SOAP, clinical and referral. No specialty count, no specialty tuning claim and no list of supported capture languages is published, so coverage cannot be compared with the enumerated ranges published by competitors in this category. Documentation output is English regardless of capture language.